Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

TCT Round-Up: The Next Generation Of Drug-Eluting Stents, Drug-Coated Balloon Featured At Washington Conference

Executive Summary

One of the world’s largest showcases for new interventional cardiology technology, the 2016 Transcatheter Cardiovascular Therapeutics (TCT) 2016 scientific sessions, were held Oct. 29-Nov. 2 in Washington, DC. This year’s edition of TCT featured many presentations on new drug-eluting coronary stent technologies, as well as drug-coated balloons for peripheral interventions.

You may also be interested in...



US Approvals Analysis: Drug-Coated Balloon, Valve Tech Are July Highlights

July was a relatively light month for novel-device approvals by US FDA, but year-to-date volumes remain strong. Spotlighted devices include approval of a new drug-coated balloon and heart valve devices. Here's a roundup from Medtech Insight's Approval Tracker.

Philips Grows Image-Guided Intervention Focus With Spectranetics Buy

In its second acquisition this month and fourth this year, Philips is buying US device maker Spectranetics Corp. for about $2bn to add laser atherectomy catheters to its vascular imaging line-up.

EuroPCR 2017: TAVR Continues To Beat Surgery; Bioabsorbable Stents Not Going Away

The EuroPCR conference in Paris is the most important annual interventional cardiology conference in Europe and this year's edition brought more data from clinical trials of both established catheter-based technologies and innovative new devices.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

MT104052

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel